2024-03-27 Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA Data Expected Mid-2024 from Ongoing Phase 1 Trial in Bladder Cancer(Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer) Strong…
2024-03-07 CuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference Drug Combination’s Unique Mechanism of Action Enables Reactivation of Brain Adrenergic Function, Showing Improvements in Multiple Areas of Cognition San Carlos, CA and Lisbon, Portugal, March 7, 2024 –…
2024-05-31 Update on Regulatory Review of NEZGLYAL® (leriglitazone) in the EU Despite CHMP upholding the negative opinion for treatment of cerebral adrenoleukodystrophy (cALD) the companies remain committed to the continued development of NEZGLYAL® for cALD Barcelona, Spain and Düsseldorf, Germany – 31 May, 2024 – Minoryx Therapeutics, a late stage biotech company focused on the development of therapies…
2024-05-8 Aura Biosciences to Participate in Upcoming Investor Conferences BOSTON, May 08, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:…
2024-05-09 Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer Enrolling; Early Data Expected Mid-2024 Strong Cash Position Expected to Fund Operations into Second Half of 2026 BOSTON, May 09, 2024 (GLOBE NEWSWIRE)…
2024-05-23 Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024 BOSTON, May 23, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will…
